- Home
- ECOR vs SCLX Comparison
ECOR vs SCLX Comparison
Compare ECOR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- SCLX
- Stock Information
- Founded
- ECOR 2005
- SCLX 2011
- Country
- ECOR United States
- SCLX United States
- Employees
- ECOR N/A
- SCLX N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- SCLX Health Care
- Exchange
- ECOR Nasdaq
- SCLX Nasdaq
- Market Cap
- ECOR 37.1M
- SCLX 35.7M
- IPO Year
- ECOR 2018
- SCLX N/A
- Fundamental
- Price
- ECOR $4.96
- SCLX $22.17
- Analyst Decision
- ECOR Strong Buy
- SCLX Strong Buy
- Analyst Count
- ECOR 2
- SCLX 3
- Target Price
- ECOR $25.50
- SCLX $367.50
- AVG Volume (30 Days)
- ECOR 99.3K
- SCLX 258.7K
- Earning Date
- ECOR 08-06-2025
- SCLX 08-13-2025
- Dividend Yield
- ECOR N/A
- SCLX N/A
- EPS Growth
- ECOR N/A
- SCLX N/A
- EPS
- ECOR N/A
- SCLX N/A
- Revenue
- ECOR $27,700,000.00
- SCLX $44,236,000.00
- Revenue This Year
- ECOR $24.48
- SCLX $89.26
- Revenue Next Year
- ECOR $44.35
- SCLX $203.95
- P/E Ratio
- ECOR N/A
- SCLX N/A
- Revenue Growth
- ECOR 30.16
- SCLX N/A
- 52 Week Low
- ECOR $4.16
- SCLX $3.60
- 52 Week High
- ECOR $19.49
- SCLX $41.30
- Technical
- Relative Strength Index (RSI)
- ECOR 41.18
- SCLX 69.02
- Support Level
- ECOR $4.74
- SCLX $17.22
- Resistance Level
- ECOR $5.32
- SCLX $19.73
- Average True Range (ATR)
- ECOR 0.34
- SCLX 1.81
- MACD
- ECOR 0.00
- SCLX 0.12
- Stochastic Oscillator
- ECOR 22.22
- SCLX 79.23
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.